GYRE
Price:
$7.69
Market Cap:
$698.60M
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. It offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under phase 3 studies for dermatomyositis and systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease. The company is also involved the development of F351 (Hydronidone), a structural derivative of ETUARY (Pirfenidone), under Phase 3 studies for the treatment of chronic hepatitis B liver fibrosis; and under Phase 1 studies for liver fibrosis asso...[Read more]
Industry
Biotechnology
IPO Date
2006-04-12
Stock Exchange
NASDAQ
Ticker
GYRE
According to Gyre Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is 192.25. This represents a change of -135.77% compared to the average of -537.50 of the last 4 quarters.
The mean historical PE Ratio of Gyre Therapeutics, Inc. over the last ten years is 17.35. The current 192.25 PE Ratio has changed 110.68% with respect to the historical average. Over the past ten years (40 quarters), GYRE's PE Ratio was at its highest in in the June 2025 quarter at 370.49. The PE Ratio was at its lowest in in the December 2024 quarter at -2600.12.
Average
17.35
Median
-15.47
Minimum
-44.16
Maximum
265.01
Discovering the peaks and valleys of Gyre Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 409.25%
Maximum Annual PE Ratio = 265.01
Minimum Annual Increase = -5671.56%
Minimum Annual PE Ratio = -44.16
| Year | PE Ratio | Change |
|---|---|---|
| 2024 | 85.20 | -605.57% |
| 2023 | -16.85 | -106.36% |
| 2022 | 265.01 | -5671.56% |
| 2021 | -4.76 | -85.45% |
| 2020 | -32.68 | 40.96% |
| 2019 | -23.19 | -47.49% |
| 2018 | -44.16 | 29.01% |
| 2017 | -34.23 | 409.25% |
| 2016 | -6.72 | -52.28% |
| 2015 | -14.09 | -65.52% |
The current PE Ratio of Gyre Therapeutics, Inc. (GYRE) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
111.12
5-year avg
59.18
10-year avg
17.35
Gyre Therapeutics, Inc.’s PE Ratio is greater than Anavex Life Sciences Corp. (-7.13), greater than Erasca, Inc. (-7.97), greater than CytomX Therapeutics, Inc. (24.71), greater than MBX Biosciences, Inc. Common Stock (-12.69), greater than MoonLake Immunotherapeutics (-5.31), greater than Astria Therapeutics, Inc. (-6.41), greater than Keros Therapeutics, Inc. (13.55), greater than MeiraGTx Holdings plc (-4.28), greater than Iovance Biotherapeutics, Inc. (-1.89), greater than ArriVent BioPharma, Inc. Common Stock (-6.24),
| Company | PE Ratio | Market cap |
|---|---|---|
| -7.13 | $359.17M | |
| -7.97 | $1.02B | |
| 24.71 | $710.51M | |
| -12.69 | $1.00B | |
| -5.31 | $942.76M | |
| -6.41 | $737.54M | |
| 13.55 | $871.17M | |
| -4.28 | $717.17M | |
| -1.89 | $729.72M | |
| -6.24 | $1.01B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Gyre Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Gyre Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Gyre Therapeutics, Inc.'s PE Ratio?
How is the PE Ratio calculated for Gyre Therapeutics, Inc. (GYRE)?
What is the highest PE Ratio for Gyre Therapeutics, Inc. (GYRE)?
What is the 3-year average PE Ratio for Gyre Therapeutics, Inc. (GYRE)?
What is the 5-year average PE Ratio for Gyre Therapeutics, Inc. (GYRE)?
How does the current PE Ratio for Gyre Therapeutics, Inc. (GYRE) compare to its historical average?